Home / Press / CMS advises shareholders of microscopy specialist...

CMS advises shareholders of microscopy specialist Luxendo on sale to Bruker Corporation

10/05/2017

Munich – Luxendo, a spin-off from the European Molecular Biology Laboratory (EMBL), has been acquired by Bruker Corporation. The Heidelberg-based firm develops and manufactures fluorescence microscopes, which use light-sheet technology to produce fast 3D imaging of living specimens. The purchase price was not disclosed.

A CMS team headed by Dr Tilman Weichert advised the Luxendo shareholders on all legal aspects of the sale. The shares were held by investors LSP and EMBL Ventures and by the European Molecular Biology Laboratory and EMBL Enterprise Management Technology Transfer GmbH. Back in 2015, CMS advised LSP and EMBL Ventures on their venture capital investment in Luxendo.

The European Molecular Biology Laboratory is an intergovernmental organisation conducting basic research in molecular biology. Established in 1974, it is supported by over 20 member states. More than 1,600 people from over 80 countries currently work at sites in Barcelona (Spain), Grenoble (France), Hamburg (Germany), Heidelberg (Germany), Hinxton (UK) and Monterotondo (Italy). The scientists work in independent groups and conduct research in all areas of molecular biology.

LSP finances private and listed life science companies. With more than a billion euros of investment capital, LSP is one of the biggest investors in the sector in Europe. LSP has financed a total of more than 100 companies over the past 25 years. It has offices in Amsterdam, Munich and Boston.

Bruker is the world leader in instrumental analytics. Headquartered in Billerica, Massachusetts, USA, the company employs more than 6,000 people at 90 locations worldwide. Bruker systems cover applications in all fields of research and development and are used in all industrial production processes. In recent years, Bruker has also become a provider of high-performance systems for cell biology, preclinical imaging, clinical microbiology and molecular pathology research.

CMS Hasche Sigle

Stefan-Ulrich Müller, Lead Partner
Dr Tilman Weichert, Counsel, Coordination
Dr Tobias Kallmaier, Senior Associate
Anton Hieber, Associate, all Venture Capital, Corporate/M&A and Lifesciences
Stefan Lüft, Partner
Theresa Dörendahl, Associate, both Intellectual Property
Gerd Schoenen, Partner
Susanne Frenz, Senior Associate, both Technology, Media & Communications
Dr Martin T. Mohr, Counsel, Tax

Press Contact
[email protected] 

Publication
Presse Release Luxendo, 10/05/2017
Download
PDF 131 kB

Related people

Stefan-Ulrich Müller
Stefan-Ulrich Müller, M. Jur. (Oxford)
Partner
Munich
Tilman Weichert
Dr. Tilman Weichert
Partner
Munich
Stefan Lüft
Stefan Lüft
Partner
Munich
Gerd Schoenen
Gerd Schoenen
Partner
Cologne
Susanne Frenz
Susanne Frenz
Counsel
Cologne
Martin Mohr
Dr. Martin Mohr
Counsel
Stuttgart
Dr. Tobias Kallmaier
Anton Hieber
Anton Hieber
Theresa Dörendahl
Theresa Dörendahl
Show more Show less